^
Association details:
| Biomarker: | NF2 deletion |
|---|---|
| Cancer: | Malignant Pleural Mesothelioma |
| Drug: | IK-930 (TEAD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma
Published date:
06/22/2022
Excerpt:
Ikena Oncology, Inc. Ikena Oncology, Inc…today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IK-930, the Company’s novel TEAD inhibitor targeting the Hippo signaling pathway, in patients with unresectable NF2-deficient malignant pleural mesothelioma (MPM).
